Menu
No results found.
Weekly Share Price & Valuation Overview
Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 2.39B
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 3.00B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- SEK 196.47M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- SEK 132.81M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- SEK 2.87
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -8.60
- Shares Outstanding
- 82.73M
- Float Shares
- 45.97M
- Implied Shares Outstanding
- 1.42M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-3.16%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
67.60%
- ROA Return on assets: net income ÷ total assets.
-
-35.83%
- Revenue Growth Strong Year-over-year revenue growth.
-
43.10%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.36
- Total Cash Cash and equivalents.
- SEK 354.42M
- Total Debt Short + long-term interest-bearing debt.
- SEK 906.21M
- Net Debt Total debt − cash (negative = net cash).
- SEK 551.79M
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.